Optimized amyloid‐β PET centiloid and cognitive cutoffs predict progression from mild cognitive impairment to Alzheimer's dementia
Optimierte Amyloid-β-PET-Centiloid- und kognitive Cutoffs sagen die Progression von milder kognitiver Beeinträchtigung zu Alzheimer-Demenz voraus
Alzheimer's & Dementia · 2026-11 · 22 (11)
DOI: 10.1002/alz.71892 ↗Auf einen Blick
Bei 454 MCI-Teilnehmenden sagten optimierte Aβ-PET- und MMSE-Cutoffs die 3-Jahres-Progression zu Alzheimer-Demenz voraus. Die höchste Progression zeigte die Gruppe mit hohem Aβ und niedrigem MMSE.
Fragestellung
Welche optimierten Aβ-PET- und MMSE-Cutoffs sagen die 3-Jahres-Progression von CDR-Global 0,5 zu 1,0 bei MCI voraus?
Methode
Analyse von 454 CDR-Global-0,5 Aβ-positiven MCI-Teilnehmenden aus AIBL und ADNI; Follow-up bis zu 7 Jahre. Optimale Cutoffs per Youden-Index; Cox- und lineare Mixed-Modelle, adjustiert für Alter, Geschlecht, Bildung und APOE ε4.
Ergebnisse
Optimale Cutoffs: Aβ-PET > 71 CL (HR 2,67; 3-Jahres-Risiko 36,7 %) und MMSE < 27 (HR 2,27; 36,8 %). Die kombinierte Hoch-Aβ/Niedrig-MMSE-Gruppe hatte ein 6,39-fach erhöhtes Risiko und 47,8 % 3-Jahres-Progression.
Schlussfolgerung der Autor:innen
Prognostisch optimierte Aβ-PET- und MMSE-Cutoffs verbesserten die 3-Jahres-Risikostratifizierung über übliche diagnostische Schwellen hinaus und unterstützen eine duale Cutoff-Anreicherung.
Kernaussagen
- Aβ-PET > 71 CL sagte 3-Jahres-Progression besser voraus
- MMSE < 27 war mit höherem Progressionsrisiko verbunden
- Kombinierter Hoch-Aβ/Niedrig-MMSE-Status zeigte die höchste Progression
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 05.11.2026. Verfasst von Rosita Shishegar und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Cognitive Dysfunction, Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Federal Government, National Health and Medical Research Council (NHMRC), National Institutes of Health (NIH)/NINDS/National Institute on Aging (NIA), Department of Defense (DOD), California Department of Public Health (CDPH), Univer….
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION This study aimed to develop optimized prognostic cutoffs for amyloid‐β–positron emission tomography (Aβ‐PET) and Mini‐Mental State Examination (MMSE) that predict 3‐year progression from Clinical Dementia Rating Global (CDR‐Global) score 0.5 to 1.0 in mild cognitive impairment (MCI) participants and validate against cognitive decline/functional trajectories. METHODS We analyzed 454 CDR‐global = 0.5 Aβ‐positive (> 25 Centiloid [CL]) MCI participants from Australian Imaging Biomarkers and Lifestyle (AIBL) ( N = 99) and Alzheimer's Disease Neuroimaging Initiative (ADNI) ( N = 355), followed up to seven years. Youden index derived optimal Aβ‐PET and MMSE thresholds for 3‐year progression. Participants were stratified into four groups by combined Aβ‐PET/MMSE status. Adjusted Cox models (age, sex, education, apolipoprotein E [ APOE] ε4) assessed progression to CDR‐Global score of 1.0 Alzheimer's disease (AD) dementia (confirmed with Aβ‐PET); adjusted linear mixed models assessed CDR Sum of Boxes (CDR‐SoB) and Preclinical Alzheimer's Cognitive Composite (PACC) trajectories. RESULTS Optimal cutoffs were Aβ‐PET > 71 CL (hazard ratio [HR] = 2.67; 3‐year risk = 36.7%) and MMSE score of < 27 (HR = 2.27; 36.8%). The combined high Aβ/low MMSE group showed a 6.39‐fold risk and 47.8% 3‐year progression, with the steepest decline. DISCUSSION Prognostically optimized Aβ‐PET and MMSE cutoffs improve 3‐year risk stratification beyond common diagnostic thresholds, supporting dual‐cutoff prognostic enrichment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia.
- School of Computing Technologies, RMIT University, Melbourne, Victoria, Australia.
- The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia.
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia.
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
- Center for Imaging of Neurodegenerative Diseases, University of California-San Francisco, San Francisco, California, USA.
Förderung
- Australian Federal Government
- National Health and Medical Research Council (NHMRC)
- National Institutes of Health (NIH)/NINDS/National Institute on Aging (NIA), Department of Defense (DOD), California Department of Public Health (CDPH), Univer…
- the Commonwealth Scientific and Industrial Research Organisation
Zitieren
APA
Shishegar, R., Doré, V., Bourgeat, P., Doecke, J. D., Cánovas, R., Laws, S. M., Porter, T., Weiner, M., Masters, C. L., Sohrabi, H. R., Fripp, J., Maruff, P., Villemagne, V. L., Rowe, C. C., & Alzheimer's Disease Neuroimaging Initiativethe Australian Imaging BiomarkersLifestyle flagship study of ageing (2026). Optimized amyloid‐β PET centiloid and cognitive cutoffs predict progression from mild cognitive impairment to Alzheimer's dementia. Alzheimer's & Dementia, 22(11). https://doi.org/10.1002/alz.71892
Vancouver
Shishegar R, Doré V, Bourgeat P, Doecke JD, Cánovas R, Laws SM, et al. Optimized amyloid‐β PET centiloid and cognitive cutoffs predict progression from mild cognitive impairment to Alzheimer's dementia. Alzheimer's & Dementia. 2026;22(11). doi:10.1002/alz.71892
BibTeX
@article{Shishegar2026,
author = {Shishegar, Rosita and Doré, Vincent and Bourgeat, Pierrick and Doecke, James D and Cánovas, Rodrigo and Laws, Simon M and Porter, Tenielle and Weiner, Michael and Masters, Colin L and Sohrabi, Hamid R and Fripp, Jurgen and Maruff, Paul and Villemagne, Victor L and Rowe, Christopher C and Alzheimer's Disease Neuroimaging Initiativethe Australian Imaging BiomarkersLifestyle flagship study of ageing, Alzheimer's Disease Neuroimaging Initiativethe Australian Imaging BiomarkersLifestyle flagship study of ageing},
title = {Optimized amyloid‐β PET centiloid and cognitive cutoffs predict progression from mild cognitive impairment to Alzheimer's dementia},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {11},
doi = {10.1002/alz.71892}
}
EUVIMED